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Abstract In investigating a possible link between a novel 
retroviral agent (provisionally called MSRV), recently charac-
terised in multiple sclerosis (MS), and the neuropathology of 
MS, it was found that there was a significant correlation between 
gliotoxicity and reverse transcriptase activity in monocyte/ 
macrophage culture supernatants (MMCS) unique to MS 
patients. MMCS from healthy controls and patients with other 
neurological diseases did not display either gliotoxicity or reverse 
transcriptase activity. The observed gliotoxic effect was an 
initial, intermediate filament network disorganization and 
subsequent cell death which was specific to astrocytes and 
oligodendrocytes. The reverse transcriptase activity and MSRV-
specific RNA were observed during the first 2 weeks of culture in 
MMCS from patients with active MS. The further elucidation of 
the molecular form(s) of this gliotoxic factor and its original 
source may be crucial in elucidating important etiopathogenic 
mechanisms in MS. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Multiple sclerosis (MS) is an autoimmune demyelinating 
disease of the human central nervous system, leading to a 
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progressive motor and sensory disability, usually over years 
of remitting-relapsing and/or chronic progressive clinical evo-
lution ([1-3] and references cited therein). It is characterised 
by multifocal plaques of demyelination with preservation of 
axons in the white matter of brain and the spinal cord, com-
monly associated with a fibrous astrogliosis in the old plaques 
[1]. Activated microglia-macrophages are associated with the 
earliest events of the lesional process in MS and contribute to 
phagocytosis of myelin debris. In acute inflammatory plaques, 
a disruption of the blood brain barrier is associated with 
oedema and massive lymphoid cell infiltration [4-8]. 
Despite extensive neuropathological studies and decades of 
multidisciplinary research, the primary cause of MS remains 
unknown. Epidemiological studies have suggested a viral ori-
gin of MS [9-11], but the etiopathological agent, if any, has 
remained elusive. A working hypothesis is that the cascade of 
pathological events as well as autoimmunity may be triggered 
by a viral agent. We have recently described retrovirus-like 
extracellular particles associated with reverse transcriptase 
(RT) activity in culture supernatants from patients with MS 
[12,13]. The first molecular data on this retrovirus (now des-
ignated MSRV, MS associated RetroVirus) have revealed 
phylogenic proximity with a human endogenous retroviral 
family represented by ERV-9 [14]. In contrast to the defective 
ERV-9 element [15], MSRV RNA is associated with extra-
cellular particles co-sedimenting with RT activity on sucrose 
gradients [16]. The MSRV polymerase RNA sequence encod-
ing the protease and the RT is compatible with that of an 
exogenous retrovirus sharing extensive homology with a fam-
ily of human endogenous retroviruses or with that of a repli-
cation-competent endogenous retrovirus [16]. Cultured blood 
monocytes from MS patients with active disease were found 
to express low but significant RT activity in the cell culture 
supernatants [13,17]. Macrophage cells are quite active in MS 
lesions as previously mentioned, as well as in visna, a natural 
animal model of MS [18-20]. In sheep infected through nat-
ural routes with the visna retrovirus, blood monocytes har-
bouring a provirus are crucial in the initiation and spreading 
of the demyelinating lesions in the central nervous system. 
However, the link between the neuropathological phenomena 
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and the retroviral expression which is genetically restricted 
and limited in space, is not obvious. Such interrogations 
have also arisen in HTLV-I and HIV-1 infections about the 
neuropathogenesis of these human retroviruses, and possible 
mechanisms of HIV-1 neurotoxicity have been explored. In 
AIDS encephalopathy, HIV-1 infected macrophages were 
found to produce a neurotoxin while HIV-1 infected and 
non-infected lymphocytes, and HIV-1 non-infected macro-
phages did not [21,22]. 
In considering the possible role of an exo/endogenous retro-
virus in MS, it was postulated that a virus-related or virus-
induced factor could be produced by monocyte/macrophage 
cell cultures from patients with active MS, and that this factor 
could affect cells from the brain parenchyma. We have there-
fore explored potential cytotoxic activities which could be co-
expressed with R T activity and M S R V R N A in the monocyte/ 
macrophage culture supernatant (MMCS) from active M S 
patients. 
2. Materials and methods 
All the cell lines were maintained at 37°C in a humidified atmo-
sphere of 5% C0 2 in air. 
2.1. Monocyte/macrophage blood cells 
Blood cells from healthy donors, patients with MS and patients 
with other neurological diseases were obtained from Grenoble 
(CHU A. Michallon, Service de Neurologie, Pr. Pellat and Pr. Perret), 
Creteil (CHU H. Mondor, Service de Neurologie, Pr. J.D. Degos) and 
from Paris (Hopital de la Salpetriere, Pr. O. Lyon-Caen). All the MS 
patients were diagnosed according to the standard criteria of Poser et 
al. [23,24,8], All blood samples and monocyte/macrophage cultures 
were processed as previously described [17]. 
2.2. Primary cortical cell cultures 
Cells were prepared from 14 days gestation Wistar rat fetal cerebral 
cortex. The tissue was minced and dissociated in F12 medium (GIB-
CO BRL) by repeated gentle trituration. The dissociated cells were 
resuspended in F12 medium supplemented with 7.5% FCS, 7.5% heat-
inactivated horse serum (GIBCO BRL), 50 U/ml penicillin (GIBCO 
BRL), 0.05 mg/ml streptomycin (Sigma) and plated onto poly L-lysine 
coated (5 ug PLL/ml in PBS, Sigma) eight-well polystyrene chamber 
slides (LAB TEK, NUNC Inc.) at a density 1X 104 cells/well. Culture 
medium was changed on day 4 and then every 2 days. Cultures were 
used for experiments 14 days after preparation. 
2.2.1. Primary rat cortical cells immunostainings. Cells were plated 
in eight-well polystyrene chamber slides and exposed to MS MMCS 
(dilution 1:4 in 200 ul) for 24 h. Cells on coverslips were fixed for 10 
min at —20°C in acetone/methanol (vol/vol, 1/1) and then incubated 
overnight at —20°C with the appropriate rabbit Ab [against GFAP 
(dilution 1:50, Boehringer) for astrocytes, against MBP and GC (di-
lution 1:50, Boehringer) for oligodendrocytes and against neurofila-
ments (dilution 1:50, Boehringer) for neurons] followed by FITC-con-
jugated goat anti-rabbit Ig (dilution 1:100). 
2.3. The mouse immortalised astroglial cell line CLTT 1-1 
Astrocytes [25] were cultured in PLL coated (5 ug/ml in PBS) plates 
in DMEM-F12 (vol/vol, 1/1, GIBCO BRL) supplemented with 10% 
FCS, 0.05 mg/ml gentamicin (GIBCO BRL). 
2.3.1. CLTT 1-1 astrocytes vimentin immunostaining. Cells were 
plated at a density 1 X 103 cell/well for 36 h before experimentation 
and exposed to MMCS for 72 h (dilution 1:20 in 200 ul). Cells on 
coverslips were washed with PBS and fixed in acetone for 10 min at 
—20°C. Cells were preincubated overnight at 4°C with mAb anti-vi-
mentin IgM (clone VIM 13,2, Sigma) at a dilution of 1:200, followed 
by FITC-conjugated goat anti-mouse IGM (dilution 1:50). All wash-
ings were carried out with PBS supplemented with 5%o FCS. 
2.4. The mouse immortalised oligodendrocyte cultures 158N 
Oligodendrocytes derived from secondary oligodendrocyte cultures 
of new-born mouse cerebral hemispheres [26] were transfected with a 
plasmid containing the SV40 T-antigen gene expressed under the con-
trol of the mouse metallothionein-1 promoter [27]. The calcium phos-
phate method was used for cell transfection. Colonies were selected 
for their resistance to G418 (Geneticin sulfate, GIBCO-BRL). After 
cloning by limit dilution, selected clones were maintained in culture in 
PLL coated (5 ug/ml in PBS) plates in DMEM (CIBCO) supple-
mented with 10%> FCS, 0.05 mg/ml gentamicin. The 158N oligoden-
drocyte culture used was immunoreactive in vitro for all three oligo-
dendrocyte proteins: myelin proteolipid protein (PLP), myelin basic 
protein (MBP) and galactocerebroside (GC) (see below). 
2.4.1. 158N oligodendrocyte cells immunostaining 
MBP and PLP immunostainings were accomplished by using rabbit 
polyclonal Ab directed against MBP and against tridecapepide corre-
sponding to the sequence 117-129 of PLP (dilution 1:50), and then 
revealed with FITC-conjugated goat anti-rabbit IgG (dilution 1:50) 
(Sigma). A mouse mAb directed against GC was used (dilution 
1:1000) and then revealed with FITC-conjugated goat anti-mouse 
IgG (R&D systems; Immunotech, Luminy). 
2.5. Qualitative live dead assay 
The assay was performed according to the procedure of MacCou-
brey et al. [28]. CLTT 1-1 astrocytes or 158N oligodendrocytes were 
cultured in PLL-coated eight-well polystyrene chamber slides (LAB 
TEK, NUNC Inc.) at a density of 2X103 cells/well 24 h before ex-
perimentation. Cells were then exposed to MMCS samples diluted in 
standard medium (dilution 1:20 in 200 ul) and incubation was con-
tinued for 72 h with no change of medium. The medium was then 
removed, the cells were washed with PBS and exposed to 2 uM calcein 
acetoxymethyl ester (Interchim) and 2 uM ethidium homodimere (In-
terchim) for 15 min at room temperature. Fluorescence microscopy 
was performed on a Carl Zeiss Axiophot microscope equipped with a 
mercury HBO 50 lamp, using BP 450-490 exciter filter (live cells) and 
BP 365 filter (both fluorophores). 
2.6. Quantitative colorimetric MTT assay 
CLTT 1-1 astrocytes were plated at a density of 2X103 cells/dish in 
60 mm plastic dishes for 24 h before experimentation. Cells were then 
exposed to different dilutions of samples in standard medium (2 ml/ 
dish) and incubation was continued for 3 days with no change in 
medium. The medium was then removed and 2 ml of MTT (0.5 mg/ 
ml in DMEM, Sigma) were added. Living cells transform the tetra-
zolium salt into dark blue formazan crystals [29]. After a 2 h incuba-
tion, the reaction was stopped by addition of 2 ml of 40 mM HC1 in 
isopropanol which solubilizes the formazan product. After a 5 min 
centrifugation at 5000 Xg, the OD was measured using a test wave-
length of 570 nm and a reference wavelength of 630 nm. Cytotoxicity 
was expressed as a percentage: % cytotoxicity = % of dead 
cells = 100-[(ODsample/ODccmtrol) X100]. 
2.7. Purification of the protein fraction associated with gliotoxic 
activity 
Samples (10 ml of MS MMCS - 42 mg of total proteins) were 
previously heated for 30 min at 56°C, pooled, centrifuged and dia-
lysed overnight at 4°C against 2 liters of PBS. The proteins were then 
applied onto a protein A sepharose column CL-4B (Pharmacia) and 
the Ig-free fraction was collected. Ig were eluted from the protein G 
column with 0.1 M glycin-HCl, pH 3.0 buffer. Toxic fraction (Ig-free 
fraction) was loaded onto a Concanavalin A Sepharose column CL-
4B (Pharmacia). Fractions containing glycosylated proteins were 
eluted first with 0.2 M D-glucopyranosid and then with 0.1 M gly-
cin-HCl, pH 3.0 and desalted through a NAP-25 column (Pharmacia) 
in order to test the toxicity. When stored after purification, the glio-
toxic material was pooled and/or aliquoted, snap-frozen in liquid ni-
trogen and placed at —80°C. 
2.8. RT-PCR with ST2 primer sets 
RNA was extracted as previously described by Chomczynski [32] 
from 2 ml of MMCS pooled from 400 ul aliquots of MMCS collected 
from the same flask on days 3, 6, 9, 12 and 15. The RNA extracted 
was resuspended in 20 ul of RNase-free water. In order to eliminate 
eventual traces of human DNA which contains irrelevant but genet-
ically homologous endogenous retroviral sequences, 7.5 ul of RNA 
solution, the cDNA mix as well as round-I and round-II PCR mix, 
were incubated with DNase as described [14] and further used for RT-
PCR as described [16] with the following modifications: first-round 
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primers (annealing temperature 54°C) were ST2.1 (upstream primer: 
5'-GAAGATCCTTTGAACCCAACGTC-3') and ST2.1 (down-
stream primer: 5'-TGGCACAAGGTTTCTGAACGG-3'), and sec-
ond-round primers (annealing temperature 60°C) were ST2.2 (up-
stream primer: 5'-CAACGTCTCAACTCACCTGGACTG-3') and 
ST2.2 (downstream primer: 5'-CGGGCGACTAAAAGTAAAT-
CATC-3'); PCR parameters were: 5 min at 94°C, 1 min at annealing 
temperature and 2 min at 72°C, 39 cycles at 94°C for 1 min, annealing 
temperature for 1 min, 72°C for 2 min, with a final extension of 2 min 
at 72°C. One JJ.1 from the first round was transferred to the second-
round PCR mix previously treated with DNase 1. For each sample, a 
second tube was always prepared in parallel with the same composi-
tion at the exception of the MoMLV reverse transcriptase, in order to 
perform a 'no-RT' control in subsequent PCR amplifications and 
validate the absence of contaminating DNA in the RNA sample 
and in the successive solutions used. An Aldolase RT-PCR was also 
made to confirm the abscence of cellular RNA in the samples. 
2.8.1. Hybridization analysis of PCR products: MSRV-pol detection 
by ELOSA. The protocol was performed essentially as previously 
described [16,33]. 
3. Results 
3.1. Cytotoxic effect of MMCS from MS patients on primary 
rat cortex embryonic cells 
Phase contrast microscopy shows that supernatants col-
lected from day 3 to day 9 in active MS cases induced cell 
death in primary cortical cell cultures from embryonic Wistar 
rat cerebral cortex (Fig. IB) or spinal cord. Equivalent 
MMCS samples from 4 healthy controls, cultured and tested 
in parallel, did not induce detectable cytotoxicity (Fig. 1A). 
Also, there was no toxicity with MMCS from 6 patients with 
other neurological diseases (one each with normal pressure 
hydrocephalus, epilepsy, encephalopathy, migraine, peripheral 
neuropathy and Guillain Barre syndrome) (data not shown). 
An immunostaining with Ab against cell-specific antigens was 
performed at different stages of these cultures, i.e., against 
neurofilaments for neurons (Fig. 1C), against GFAP for as-
trocytes, and against MBP and GC for oligodendrocytes. The 
data for astrocytes and oligodendrocytes in treated cells are 
not shown since no staining was observed. In these primary 
brain cultures, the astroglial layer first exhibited a cytolytic 
process while the neurons appeared to be well preserved (Fig. 
IB, C). During longer periods of incubation (48 to 72 h), 
nearly complete destruction of the astrocytes and oligoden-
drocytes populations was observed (data not shown). Signifi-
cant astrocyte and oligodendrocyte cytotoxicity was detect-
able after 24 h of incubation. This immunoanalysis therefore 
suggests that astrocytes and oligodendrocytes are the primary 
target for this toxic activity. The neurons only started to de-
generate after massive depletion of glial cells in vitro. This late 
neuronal degeneration was presumably due to the deprivation 
of the astroglial feeder-layer. 
3.2. Cytotoxic effect of MMCS from MS patients on 
immortalised astrocytes and oligodendrocytes 
The supernatants from the three day periods, day 3 to day 6 
and day 6 to day 9, were pooled for both the control and MS 
samples. These pooled supernatants were added to immortal-
ised astrocytes CLTT 1-1 cultures [25] and to immortalised 
oligodendrocyte-enriched cultures 158N [26]. A qualitative 
study of cell death was first performed using the fluorescence 
method of MacCoubrey et al. [28] in order to distinguish live 
and dead cells. A high incidence of death of CLTT 1-1 im-
mortalised astrocytes was demonstrated by the nucleic stain-
ing of dying cells by ethidium homodimer (Fig. 2B) compared 
to the controls (Fig. 2A). This same effect was also observed 
on immortalised oligodendrocyte cultures (Fig. 2C, D). It 
confirmed that immortalised astrocytes and oligodendrocytes 
are sensitive to this toxic activity. 
3.3. Partial purification and dose-response effect of partially 
purified MMCS on immortalised CLTT 1-1 astrocytes 
In order to obtain quantitative data on the MMCS-induced 
glial cell death, we used the MTT assay. Since culture media 
could contain many active components, we performed a 
partial purification, as described in Section 2.7, which resulted 
Fig. 1. Phase-contrast microscopy of primary rat cortical cells exposed to crude MMCS from healthy donor and MS patient. Primary mouse 
cortical cell culture generated from embryonic (El4) cortical tissue was exposed at 14 days post-seeding for 24 h to healthy donor MMCS (A) 
and MS MMCS (B) at a dilution of 1:4 in 2 ml of culture medium. Phase-contrast X400. (C) represents the positive neurofilaments immuno-
staining of neurons exposed to MS MMCS (X400). Astrocytes and oligodendrocytes were not stained by their characteristic Ab (against 
GFAP for astrocytes and against MBP and GC for oligodendrocytes, data not shown). 
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Fig. 2. Cytotoxic effect of MMCS from MS patients on immortalised mouse astrocytes and 158N oligodendrocytes cell lines. Non confluent as-
trocytes (A, B) and oligodendrocytes (C, D) cells were exposed to MMCS from a healthy donor (A, C) and from a MS patient (B, D) for 72 h 
(dilution 1:20). Live and dead cells were distinguished by green and red fluorescence, respectively (X40). 
in a 76% recovery of toxic activity (Table 1). Purified toxic 
fractions were analysed for protein composition on 
SDS-PAGE (Fig. 3A). Elution of the protein from the gel 
and SDS removal demonstrated that gliotoxicity was 
essentially recovered in the 17-kDa gel region (data not 
shown). The same purification was also performed with 
10 ml of MMCS from healthy donors. No toxicity was re-
covered at each step. Increasing dilutions of partially puri-
fied MMCS were tested starting from an initial 1:20 dilu-
tion with resulting cytotoxicity of about 53%. Fig. 3B 
illustrates the dose-response effect observed with the MMCS 
from active MS cases. Cell survival was decreased with 
increasing amounts of the toxic, partially purified MS 
MMCS sample, in a dose dependent manner. MMCS from 
controls corresponding to the highest concentration on this 
curve (1:20) did not induce cell death. 
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3.4. Disorganization of the vimentin network in immortalised 
CLTT 1-1 astrocytes exposed to MS MMCS 
Some insight into the cellular modifications accompanying 
cytotoxic effects in glial cells was obtained by studying the 
cytoskeletal organization of the cells exposed to MS 
MMCS. Attention was paid to intermediate filaments, since 
we had observed important modifications in the glial cell 
shape as an early cytotoxic event, and in particular, to vimen-
tin, since GFAP is synthesised at low levels in proliferating 
CLTT 1-1 cells. The GFAP synthesis increases at confluence 
[34], but our observations require low density cultures with 
proliferating astrocytes. In previous studies, the gliotoxic ef-
fect was only seen with rapidly dividing cells and not with 
cells at confluence (data not shown). Aliquots of MS 
MMCS with known gliotoxicity were added to eight-well 
chamber slides coated with dividing CLTT 1-1 astrocytes. 
After 24 to 48 h of incubation, many CLTT 1-1 cells displayed 
an abnormal distribution of vimentin, with disorganised cyto-
plasmic networks (Fig. 3D). This was not observed in wells 
incubated with control MMCS (Fig. 3C). It was also con-
firmed by Western blot that vimentin monomers were not 
hydrolysed in MS MMCS treated astrocytes (data not 
shown). This diffuse labeling of vimentin correlated with an 
initial cytotoxic effect and was therefore suggestive of intra-
cytoplasmic depolymerization. 
3.5. Correlation of cytotoxic activity and reverse transcriptase 
activity 
Since a significant gliotoxicity associated with cultures from 
MS patients was observed, it was decided to analyze for any 
correlation between this cytotoxicity and the RT activity pre-
viously reported in MMCS from 'active' MS patients 
[13,17,30]. The results are presented for both the gliotoxic 
activity measured by the MTT assay on CLTT 1-1 cells 
(Fig. 4A) and the RT activity measured on ultracentrifugation 
pellets in MMCS (Fig. 4B) from 3 patients with differing MS 
stages and one healthy control. At sampling, patient MSI had 
a chronic-progressive form in a quickly progressive phase, 
MS2 had a relapsing-remitting form and was in relapse, and 
MS3 had a relapsing-remitting form and was in remission for 
more than 6 months. The MMCS, harvested and completely 
renewed every three days, were pooled for the periods between 
days 3 to 6 and 9 to 15. The supernatants from day 1, which 
preceded macrophage differentiation, was tested separately 
[17]. Significant gliotoxicity (Fig. 4A) and RT activity (Fig. 
4B) were detected in samples from MSI and MS2, with high-
est levels from day 3 to 6. Lower activities were detected in the 
MS3 culture and only background activities were present in 
the control supernatant. Since the culture medium was com-
pletely replaced every three days and the cells washed before 
medium replacement, the presence of toxicity in subsequent 
media is consistent with an in vitro production of a gliotoxic 
factor in monocytes/macrophages cells. This in vitro produc-
tion was also observed for RT activity. In Fig. 4C, mean RT 
activity data, abscissa, was plotted against mean gliotoxicity 
data, ordinate, for the MSI, MS2, MS3 and control data 
given in Fig. 4A, B. A significant correlation was observed 
between the RT activity data and gliotoxicity data with a 
correlation coefficient (r) of 0.89 and a probability (P) for 
the test of significance of the slope [35] of 0.0001, thus sug-
gesting a pathophysiological link between retroviral and glio-
toxic factors. The RT activity and gliotoxicity were observed 
in the MSI and MS2 groups and are the basis for the ob-
served correlation. MS3 and control data were at background 
levels (0-2000 dpm for RT-activity and 0-10% for gliotoxic-
ity). Additionally, cultures from 10 different control patients 
and 6 patients with other neurological diseases were analysed. 
They did not present any toxicity and RT activity (data not 
shown). 
3.6. Absence of correlation with cytokines potentially involved 
in the MS inflammatory response 
In order to evaluate the kinetics of cytokine production in 
our MMCS from MS patients, patients with other neurolog-
ical diseases, and healthy controls, we measured the levels of 
GM-CSF, TNF-oc, IL-1(3 and IL-6 using the specific ELISA 
assays (R&D System Cytokine ELISA kits) between day 3 
and day 15 in a series of cultures. GM-CSF was detected in 
practically all the MMCS tested. However its levels appeared 
to be lower in healthy controls and it was not detected in one 
MS MMCS. TNF-oc was not detected in all the MMCS tested 
except in the MMCS from a patient with Wegener's disease. 
IL-lp and IL-6 were found at day 3 and 6 in several MS and 
controls MMCS, with higher levels in healthy controls. No 
correlation has been found between RT activity and the pro-
duction of cytokines in MS MMCS (data not shown). None 
of the known cytokines tested in parallel on CLTT 1-1 astro-
cytes cultures displayed any significant cytotoxic activity 
under the conditions of our gliotoxicity assays (manuscript 
in preparation). 
3.7. Detection of specific MSRV RNA in cell-free MS MMCS 
Since the nucleotide sequence of a retroviral pol gene in 
RNA from MS virions has recently been characterised [16] 
and attributed to a novel retrovirus (MSRV), MS and con-
trols MMCS were analysed by RT-PCR with specific MSRV 
primers and probes. Supernatants from each culture were 
pooled from day 3 to day 15 and RNA was extracted from 
500 pi of each pool. A nested RT-PCR was performed with 
MSRV primers, followed by hybridization of the PCR prod-
Table 1 
Summary of the purification steps 
Purification steps 
Initial supernatant 
Protein A sepharose C1-4B 
Con A sepharose+NAP-25 
Total proteins 
(mg) 
42 
35.3 
0.32 
Total toxicity 
(dead cells) 
700000 
654000 
533 335 
Specific toxicity 
(dead cells/mg) 
16600 
18 530 
166667 
Toxicity yield 
(%) 
100 
93 
76 
The protein concentrations were measured by the method of Bradford [40] using BSA as reference and toxicity was determined on immortalised 
mouse CLTT 1-1 astrocytes using the MTT assay. Each result is the average of three experiments, each run in triplicate. Cytotoxicity represents the 
cell death at 72 h. The Ig fraction, the proteins directly eluted from the Concanavahn A column and the protein eluted with 0.2 M D-glucopyranosid 
did not present any toxicity (data not shown). The yield represents the percentage of toxic activity recovered after the purification steps as 
compared to the initial supernatant toxicity. 
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Fig. 3. (A) Protein composition from a 50 ul sample of partially-purified MS MMCS analysed on a 10% SDS-Page gel. Proteins were visualised 
by silver nitrate staining. Lane 1 represents the MW markers (albumin, ovalbumin, carbonic anhydrase, trypsin inhibitor and a-lactalbumin, se-
quentially). Lanes 2 and 3 correspond to the MMCS before purification and to the non retained proteins on concanavalin A, respectively. 
Lanes 3 and 4 represent the glycosylated proteins eluted with 0.2 M D-glucopyranosid and 0.1 M glycin HC1 pH 3, respectively. The arrow in-
dicates the toxic protein recovered after elution from the gel and SDS removal. (B) Dose-response curve of cell death in astrocyte cultures after 
exposure to toxic MMCS. CLTT 1-1 astrocytes were exposed to MS MMCS partially purified proteins at the indicated dilutions for 72 h. Cy-
totoxicity was evaluated by determining the surviving cells using the MTT assay and expressed as a percentage of cell death, compared to un-
treated control cultures. Each result is the mean of data obtained in three separate experiments, each performed in three replicate wells. Bars 
represent ± S.E.M. (C) and (D) Immunofluorescence analysis of vimentin network on mouse immortalised astrocytes exposed to MMCS. 
CLTT 1-1 astrocytes were exposed to purified healthy donor MMCS (C) or purified gliotoxic fraction from MS MMCS (D) for 48 h at a dilu-
tion of 1:20. Cells on coverslips were fixed in acetone for 10 min at —20°C. The cells were incubated with mAb anti-vimentin IgM, followed 
by FITC-conjugated goat anti-mouse IgM (see Section 2.3). 
ucts with MSRV-specific capture and detection probes (ELO-
SA technique). In parallel, 'pan-retrovirus' pol primers were 
used in RT-PCR and the presence of a MSRV corresponding 
region was detected by specific hybridization with MSRV 
probes in the ELOSA technique [14,16]. In Table 2, the ELO-
SA results on RT-PCR products from MS and control 
MMCS, indicate the presence of MSRV RNA in cell-free 
MMCS from two MS patients only (K and LE). LE was 
found positive with two techniques and K with one only. 
This may be explained by sequence variations which cannot 
be amplified during RT-PCR using the chosen ST2 MSRV pol 
primers at the stringent annealing temperature, but are ampli-
fied by the corresponding 'pan-retro' primers and further de-
tected by specific MSRV ELOSA. Alternatively, thermody-
namics generated by the target, the primers and the RT-
PCR conditions might render one technique more sensitive 
than the other. Two kinds of controls were measured in par-
allel with these RT-PCR, one consisted of a 'no-RT' control 
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Fig. 4. Correlation between the presence of cytotoxic activity and 
reverse transcriptase activity in MS MMCS. MMCS from a healthy 
donor (control) and MS patients at different stages of the disease 
(MSI, chronic progressive; MS2, relapsing-remitting at relapse; and 
MS2, relapsing-remitting at remission) were removed, pooled (day 1, 
from days 3 to 6 and from days 9 to 15) and analysed for cytotox-
icity (A) and RT activity (B). Cytotoxicity and RT values are the 
mean of three experiments run in triplicate and bars represent 
±mean deviation. (C) illustrates the correlation between cytotoxicity 
and RT activities data. Correlation coefficient, r = 0.89. 
which was designed to ascertain the absence of DNA, which 
contains endogenous homologs, in our RNA preparations (see 
Table 2), and another consisted of a RT-PCR with human 
aldolase primers in order to ascertain the absence of contam-
inating cellular RNA from occasional cells shedded or lysed, 
in the supernatants. None of these RNAs extracted from 
MMCS contained cellular DNA or RNA. The gliotoxicity 
assay and the RT-PCR were made in two independent labo-
ratories by two different persons unaware of the origin (MS or 
control) of the samples and unaware of any result independ-
ently obtained with them. A strict coincidence is observed 
between the presence of a significant gliotoxic activity peak 
in MMCS during the time-course of the culture and the de-
tection of a specific 'extracellular' MSRV RNA by RT-
PCR+ELOSA in the MMCS pooled over the corresponding 
period. 
4. Discussion 
The etiopathogenesis of MS stands at the cross-roads of 
immunology, microbiology and neurobiology and we are con-
vinced that its elucidation requires an integrated multidisci-
plinary approach. A few years ago, we had obtained a lepto-
meningeal cell-culture (LM7) from cerebrospinal fluid of a 
patient with an acute relapse of MS in which we detected 
retro virus-like RT-activity and extracellular particles [12]. A 
similar observation was obtained in larger series of patients 
when we adapted blood monocyte culture to the detection of 
this retroviral activity [13]. We later confirmed the association 
of a specific retroviral RNA with these extracellular virions, 
and the apparent association between MS activity and their 
release in MMCS [17,14]. We also observed retroviral-like 
particles produced by MS MMC in phase with a burst of 
RT activity [13]. 
The retroviral genome associated with these virions has 
been characterised as that of an oncovirus and is closely re-
lated to a family of human endogenous elements (ERVs). The 
current nucleotide sequence information on this novel retro-
virus, now designated MSRV, is compatible with that of an 
exogenous retrovirus sharing extensive homology with partic-
ular ERVs or with a replication-competent ERV harboured 
by the genome of susceptible individuals and activated by co-
factors such as herpes viruses [36,16]. These notions are well-
known in animal retroviral families such as murine leukaemia 
and mouse mammary tumour viruses in which pathogenic 
strains can be exogenous or endogenous and share more 
Table 2 
MSRV and pan-retro RT-PCR on MMCS: MSRV-specific ELOSA results 
Control cDNA 
MS K 
MS L 
MS LE 
MS R 
Healthy control 
MSRV RT-PCR 
No RT-PCR 
VI 
0.021 
0.007 
0.010 
0.034 
0.006 
0.010 
V2 
0.010 
0.006 
0.028 
0.006 
0.007 
0.006 
RT-PCR 
VI 
0.007 
0.005 
0.013 
0.118 
0.044 
0.008 
V2 
0.007 
0.005 
0.015 
0.102 
0.011 
0.008 
'Pan-retro' RT-PCR 
No RT-PCR 
VI 
0.022 
0.026 
0.020 
0.028 
NI 
0.045 
V2 
0.017 
0.011 
0.017 
0.031 
NI 
0.035 
RT-PCR 
VI 
0.01 
2.409 
0.018 
1.684 
NI 
0.010 
V2 
0.014 
2.602 
0.013 
1.469 
NI 
0.008 
Gliotoxicity 
MTT test (%) 
8 
0 
12 
0 
0 
ELOSA results are expressed as OD units. The cut-off value of the technique is 0.050. VI and V2 are the duplicate ELOSA values [16,31,33]. The 
control cDNA represents a cDNA made in parallel with the others, with water in place of the RNA extracted from each sample. NI, not 
interpretable. Gliotoxicity represents the maximum value during the considered period of culture; background activity with reference samples 
was inferior to 5% in these series. 
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than 90% of homology in their nucleotide sequences. However 
this field remains quite unexplored in humans, despite many 
studies arguing in favor of a pathogenic role of such retro-
viruses in autoimmune diseases (for review, see [37]). If we 
consider the considerable technical and ethical difficulties to 
definitely establish a direct or indirect link between this cat-
egory of agents and a human disease, the present study, re-
sulting from our multidisciplinary approaches, is certainly a 
way to evaluate such a link. 
The results presented in this report address the following 
points: 
1. Monocytes isolated from peripheral blood, and cultured 
in our conditions, produce significant levels of gliotoxic 
activity, when obtained from patients with active MS. 
2. The corresponding culture supernatants induce both as-
trocytes and oligodendrocytes cell death in primary 
mouse cortical cultures. Cell death was also observed 
in immortalised astrocytes and oligodendrocytes in a 
characteristic dose-dependent way. The phenomenon 
of filament disorganization precedes cell death, but its 
relationship with the subsequent cell death must be fur-
ther evaluated. However, such a relationship has been 
discussed in a study of viral infections [38,39] where 
there was an induced intermediate network disorganiza-
tion triggered by adenoviral products. 
3. This gliotoxic activity does not result from the progres-
sive dilution in cell culture of a toxic factor present in 
MS plasma, since long-term kinetics indicate successive 
'waves' of gliotoxic activity released in MS MMCS (data 
not shown). The variations observed are thus consistent 
with an active process associated with the cultured cells. 
4. The release of a significant gliotoxic activity during the 
first two weeks of culture is apparently correlated with 
significant RT activity, and MSRV-specific RNA can be 
detected in cell-free 'active' MS MCCS. 
5. The present results and those of complementary study 
(manuscript submitted) show that the observed gliotox-
icity cannot be attributed to already characterised hu-
man cytokines, at present. 
We cannot say at present whether the gliotoxic activity is 
due to an MSRV-encoded structural or regulatory protein, or 
to a host's cellular factor subsequently induced by this retro-
virus. However, the apparent coincidence between gliotoxic 
and RT-activities in MMCS from patients with active MS 
suggests interesting directions for further studies addressing 
the potential pathogenic role of MSRV replication in MS. 
The fact that monocytes/macrophages from MS patients are 
able to produce a gliotoxic activity may ultimately be related 
to several unique neuropathological features of MS, like 
blood brain barrier disruption and demyelination, and could 
also explain the presence of the gliotoxic activity in MS cer-
ebrospinal fluid [41], if monocytes/macrophages are the priv-
ileged source of the gliotoxic factor(s). We are currently pur-
suing the molecular characterization of the protein associated 
with this gliotoxic activity which can also be purified from 
cerebrospinal fluid of MS patients. 
Knowing the difficulties to address the relationship between 
endo/exogenous retroviruses and human diseases, the patho-
genic link provided by this gliotoxic activity may be crucial in 
elucidating important etiopathogenic mechanisms in MS. 
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